Claims for Patent: 8,980,873
✉ Email this page to a colleague
Summary for Patent: 8,980,873
| Title: | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.- 1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt |
| Abstract: | The present invention relates to certain salts of a 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1- .1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (Compound I) which have been found to have improved properties. In particular the present invention relates to the citrate salt of this compound. The invention also relates to pharmaceutical compositions containing the citrate salt and methods of use of the citrate salt in the treatment of certain medical conditions. ##STR00001## |
| Inventor(s): | Dymock; Brian (Singapore, SG), Lee; Cheng H. (Singapore, SG), William; Anthony D. (Singapore, SG) |
| Assignee: | CTI Biopharma Corp. (Seattle, WA) |
| Application Number: | 13/133,297 |
| Patent Claims: |
1. A crystalline citrate salt of 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1-
.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene which shows on X-ray diffraction a peak on the 2theta scale at 22.4.degree..+-.0.5.degree..
2. A salt according to claim 1 wherein the salt is the 1:1 salt. 3. A salt according to claim 1 which also shows on X-ray diffraction peaks on the 2theta scale at 10.2.degree..+-.0.5.degree. and 15.7.degree..+-.0.5.degree.. 4. A salt according to claim 1 which shows on X-ray diffraction at least four peaks on the 2theta scale selected from the group consisting of 7.8.degree..+-.0.5.degree., 10.2.degree..+-.0.5.degree., 14.2.degree..+-.0.5.degree., 15.7.degree..+-.0.5.degree., 16.8.degree..+-.0.5.degree., 21.4.degree..+-.0.5.degree., and 22.4.degree..+-.0.5.degree.. 5. A salt according to claim 4 which shows on X-ray diffraction at least 6 peaks on the 2theta scale selected from the group consisting of 7.8.degree..+-.0.5.degree., 10.2.degree..+-.0.5.degree., 14.2.degree..+-.0.5.degree., 15.7.degree..+-.0.5.degree., 16.8.degree..+-.0.5.degree., 21.4.degree..+-.0.5.degree., and 22.4.degree..+-.0.5.degree.. 6. A salt according to claim 4 which shows on X-ray diffraction peaks on the 2theta scale at 7.8.degree..+-.0.5.degree., 10.2.degree..+-.0.5.degree., 14.2.degree..+-.0.5.degree., 15.7.degree..+-.0.5.degree., 16.8.degree..+-.0.5.degree., 21.4.degree..+-.0.5.degree., and 22.4.degree..+-.0.5.degree.. 7. A salt according to claim 6 which also shows on X-ray diffraction peaks on the 2theta scale at 10.9.degree..+-.0.5.degree., 17.1.degree..+-.0.5.degree., 23.3.degree..+-.0.5.degree., 25.1.degree..+-.0.5.degree., 25.8.degree..+-.0.5.degree., and 27.5.degree..+-.0.5.degree.. 8. A salt according to claim 7 which also shows on X-ray diffraction peaks on the 2theta scale at 7.2.degree..+-.0.5.degree., 17.6.degree..+-.0.5.degree., 18.5.degree..+-.0.5.degree., 18.7.degree..+-.0.5.degree., 20.7.degree..+-.0.5.degree., 23.1.degree..+-.0.5.degree., 24.2.degree..+-.0.5.degree., 26.2.degree..+-.0.5.degree., 26.9.degree..+-.0.5.degree., 28.7.degree..+-.0.5.degree., 29.3.degree..+-.0.5.degree., 31.0.degree..+-.0.5.degree., 32.4.degree..+-.0.5.degree., 37.3.degree..+-.0.5.degree., 38.6.degree..+-.0.5.degree., 39.9.degree..+-.0.5.degree.and 41.6.degree..+-.0.5.degree.. 9. A pharmaceutical composition comprising a salt according to claim 1. 10. A method of treating cancer comprising administration of a therapeutically effective amount of a salt according to claim 1 to a patient in need thereof, wherein the cancer is selected from the group consisting of colon cancer, acute myeloid leukaemia and myelofibrosis. 11. A method according to claim 10 wherein the cancer is colon cancer. 12. A method according to claim 10 wherein the cancer is acute myeloid leukaemia. 13. A method according to claim 10 wherein the cancer is myelofibrosis. |
